|
|
|
|
|
|
Employers Tap Executives for Temporary Jobs
|
5/21/2008
|
WSJ -- Over the past five years, John Delaney has worked at four hospitals across the U.S. But the human-resources executive isn't a job hopper -- at least not in the traditional sense. Rather, Mr. Delaney is among a small but growing number of executives who are lending their expertise to employers in need of temporary...
BioSpace.com
|
|
FDA Stresses Birth Defect Risks with Novartis AG and Roche Holding AG Drugs
|
5/19/2008
|
WASHINGTON (Reuters) - U.S. health officials issued an alert on Friday about the risk of first-trimester miscarriages and birth defects from Novartis AG and Roche Holding AG transplant drugs.
BioSpace.com
|
|
Aprotinin Used In Heart Surgery Associated With Increased Risk Of Death, Ottawa Health Research Institute, The Ottawa Hospital, and University of Ottawa Study Shows
|
5/16/2008
|
OHRI -- Aprotinin is associated with a 50 per cent increase in the relative risk of death, according to a major Canadian clinical trial comparing three drugs routinely used to prevent blood loss during heart surgery. The trial, published in the New England Journal of Medicine, shows that approximately six per cent of patients who received aprotinin died within ...
BioSpace.com
|
|
Antisoma PLC To Acquire Xanthus Pharmaceuticals, Inc. For USD $52.2M
|
5/16/2008
|
London, UK, May 16, 2008 - (ABN Newswire) - London, UK, and Boston, MA: 16 May 2008 Cancer-focused biotechnology company Antisoma plc (LSE: ASM; US OTC: ATSMY) today announces that it has entered into an agreement to acquire private US oncology company Xanthus Pharmaceuticals, Inc. in an all-share deal valued at GBP ...
BioSpace.com
|
|
Sorin Group S.p.A. Announces FDA Approval of the World's Smallest Cardiac Resynchronization Implantable Cardioverter Defibrillator: OVATIO(TM) CRT
|
5/16/2008
|
DENVER, Colo.--(BUSINESS WIRE)--The Sorin Group (MIL:SRN), the largest European cardiovascular company and world leader in medical technologies for cardiac surgery, announces the U.S. Food and Drug Administration’s (FDA) approval to market the CRT model of its OVATIO™ family. Coupled together with the Situs...
BioSpace.com
|
|
Dynavax Technologies Corporation Ends Development Of Allergy Drug Tolamba After Trial Failure
|
5/16/2008
|
AP -- Dynavax Technologies Corp. Friday said that it is ending development of its ragweed allergy drug Tolamba after it failed a midstage trial. The drug developer said that it the drug did not show a significant improvement over placebo in reducing nasal symptoms.
BioSpace.com
|
|
Doribax Shows Shorter Hospital Stays In Ventilator-Associated Pneumonia Patients, Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) Study
|
5/16/2008
|
EurekAlert -- The investigational use of doripenem for the treatment of ventilator-associated pneumonia (VAP) was associated with shorter patient length of stay and reduced hospital resource utilization, according to new data published in the April edition of Clinical Therapeutics. The total number of hospital days and time on mechanical ventilation were significantly shorter for patients treated with doripenem compared to the commonly used imipenem...
BioSpace.com
|
|
Acne Drug Doxycycline Prevents Tissue Damage From Emphysema, Leeds University and University of California, San Diego (UCSD) Study
|
5/16/2008
|
ScienceDaily — An antibiotic commonly used to treat acne can prevent tissue damage caused by lung diseases such as emphysema, researchers have found.
BioSpace.com
|
|
Johnson & Johnson Recalling Certain Lots Of Drugs After Theft
|
5/16/2008
|
Reuters - Johnson & Johnson said on Thursday it was voluntarily recalling specific lots of three of its medicines to protect patients from receiving potentially mishandled or damaged products after a truck carrying the drugs was stolen.
BioSpace.com
|
|
AGA Medical Corporation Receives CE Mark Approval for the AMPLATZER(R) Vascular Plug III
|
5/16/2008
|
|
MINNEAPOLIS, May 15 /PRNewswire/ -- AGA Medical Corporation ("AGA") announced today it received CE mark approval to market the AMPLATZER(R) Vascular Plug III ("AVP III"). AGA also announced the immediate availability and launch of the device in the European Union. The AVP III further expands the AGA family of occlusion devices designed to embolize...
BioSpace.com
|
|
|
|
|